MX368536B - Composicion farmaceutica para el tratamiento de helicobacter pylori. - Google Patents
Composicion farmaceutica para el tratamiento de helicobacter pylori.Info
- Publication number
- MX368536B MX368536B MX2015010490A MX2015010490A MX368536B MX 368536 B MX368536 B MX 368536B MX 2015010490 A MX2015010490 A MX 2015010490A MX 2015010490 A MX2015010490 A MX 2015010490A MX 368536 B MX368536 B MX 368536B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pharmaceutical compositions
- helicobacter pylori
- pylori
- infection
- Prior art date
Links
- 241000590002 Helicobacter pylori Species 0.000 title 1
- 229940037467 helicobacter pylori Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008184 oral solid dosage form Substances 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a una cápsula, que comprende: (1) una primera composición de dosificación de liberación inmediata en forma de minitabletas comprimidas, la primer composición de dosificación de liberación inmediata comprende al menos dos antibióticos; (2) una segunda composición de dosificación de liberación retardada en forma de minitabletas comprimidas, la segunda composición de dosificación de liberación retardada comprende un inhibidor de la bomba de protones y un revestimiento, en donde, cuando se prueba en un aparato de canastilla, el revestimiento de la segunda composición de dosificación de liberación retardada está suficientemente diseñado para cumplir con el perfil de disolución de prueba de dos etapas en un aparato de canastilla: (a) liberación de no más del 10% en peso del inhibidor de la bomba de protones en 120 minutos en una fase ácida que comprende 900 ml de HCI 0.1 N a 100 rpm; y (b) libración de no menos del 75% en peso del inhibidor de la bomba de protones en 45 minutos en 900 ml de tampón de fosfato pH 6.8 a 100 rpm después de la etapa de ácido. .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764401P | 2013-02-13 | 2013-02-13 | |
| US201361764385P | 2013-02-13 | 2013-02-13 | |
| PCT/US2014/016071 WO2014127025A1 (en) | 2013-02-13 | 2014-02-12 | Pharmaceutical compositions for the treatment of helicobacter pylori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015010490A MX2015010490A (es) | 2015-10-30 |
| MX368536B true MX368536B (es) | 2019-10-07 |
Family
ID=51297592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010490A MX368536B (es) | 2013-02-13 | 2014-02-12 | Composicion farmaceutica para el tratamiento de helicobacter pylori. |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US9050263B2 (es) |
| EP (1) | EP2956149B1 (es) |
| JP (1) | JP6494529B2 (es) |
| KR (1) | KR102062357B1 (es) |
| CN (2) | CN105163743A (es) |
| AU (1) | AU2014216373B2 (es) |
| BR (1) | BR112015019264B1 (es) |
| CA (1) | CA2900763C (es) |
| CL (1) | CL2015002253A1 (es) |
| CY (1) | CY1122113T1 (es) |
| DK (1) | DK2956149T3 (es) |
| ES (1) | ES2744406T3 (es) |
| HK (1) | HK1217645A1 (es) |
| HR (1) | HRP20191559T1 (es) |
| HU (1) | HUE052411T2 (es) |
| IL (1) | IL240387B (es) |
| MX (1) | MX368536B (es) |
| NZ (1) | NZ711754A (es) |
| PH (1) | PH12015501783A1 (es) |
| PL (1) | PL2956149T3 (es) |
| PT (1) | PT2956149T (es) |
| RU (1) | RU2671400C2 (es) |
| SG (1) | SG11201506318QA (es) |
| SI (1) | SI2956149T1 (es) |
| UA (1) | UA120249C2 (es) |
| WO (1) | WO2014127025A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102062357B1 (ko) | 2013-02-13 | 2020-01-03 | 레드힐 바이오파마 엘티디 | 헬리코박터 파일로리 치료용 약제학적 조성물 |
| KR101884230B1 (ko) * | 2016-02-29 | 2018-08-01 | 주식회사 유영제약 | 에소메프라졸을 포함하는 제제 |
| JP2018149269A (ja) * | 2017-01-18 | 2018-09-27 | マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル | 消化管感染症に対する管腔内治療システム |
| EP3551186A4 (en) * | 2017-10-15 | 2020-08-19 | The Center for Digestive Diseases | COMPOSITIONS AND METHODS FOR THE TREATMENT, IMPROVEMENT AND PREVENTION OF H. PYLORI INFECTIONS |
| CN108497546B (zh) * | 2018-03-22 | 2021-03-19 | 宝可科技（上海）有限公司 | 一种烟用添加剂及其制备方法和用途 |
| CN110354125A (zh) * | 2019-08-12 | 2019-10-22 | 珠海赛隆药业股份有限公司 | 一种治疗幽门螺杆菌感染的组合物及其制剂和用途 |
| US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
| KR20230150745A (ko) * | 2022-04-22 | 2023-10-31 | 한국생명공학연구원 | 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN117398360B (zh) * | 2023-12-14 | 2024-03-15 | 山东齐都药业有限公司 | 治疗幽门螺杆菌的复方制剂胶囊及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3980637A (en) * | 1975-03-17 | 1976-09-14 | Bristol-Myers Company | Production of amoxicillin |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| EP0941101A1 (en) | 1996-11-22 | 1999-09-15 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| SE9700885D0 (sv) | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| AUPP325398A0 (en) * | 1998-04-30 | 1998-05-21 | Borody, Thomas J. | Improved method for eradicating h. pylori |
| US5927500A (en) * | 1998-06-09 | 1999-07-27 | Milliken & Company | Pharmaceutical containment package |
| JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
| US20040213847A1 (en) * | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
| WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP1803450A1 (en) * | 2006-01-03 | 2007-07-04 | Ferrer Internacional, S.A. | Pharmaceutical compositions for the eradication of helicobacter pylori |
| US8383151B2 (en) * | 2007-07-06 | 2013-02-26 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| JP5260905B2 (ja) | 2007-07-12 | 2013-08-14 | 株式会社ジャパンディスプレイ | 有機ｅｌ表示装置 |
| JP5032577B2 (ja) | 2007-07-20 | 2012-09-26 | 興和株式会社 | 鉛濃度測定用試薬及び鉛濃度測定方法 |
| MX2010001071A (es) * | 2007-07-27 | 2010-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas pulsatiles. |
| CN101584681A (zh) * | 2008-05-23 | 2009-11-25 | 黑龙江福和华星制药集团股份有限公司 | 一种用于治疗幽门螺旋杆菌感染的片剂胶囊 |
| CN101607086B (zh) * | 2009-07-21 | 2011-11-02 | 山西安特生物制药股份有限公司 | 一种复方铋剂组合物及其制备方法 |
| CN102091084B (zh) * | 2010-12-09 | 2012-05-09 | 王勇 | 一种复方胶囊及其制备方法 |
| KR102062357B1 (ko) * | 2013-02-13 | 2020-01-03 | 레드힐 바이오파마 엘티디 | 헬리코박터 파일로리 치료용 약제학적 조성물 |
-
2014
- 2014-02-12 KR KR1020157023788A patent/KR102062357B1/ko active IP Right Grant
- 2014-02-12 US US14/179,197 patent/US9050263B2/en active Active
- 2014-02-12 DK DK14751025.9T patent/DK2956149T3/da active
- 2014-02-12 SG SG11201506318QA patent/SG11201506318QA/en unknown
- 2014-02-12 BR BR112015019264-5A patent/BR112015019264B1/pt active IP Right Grant
- 2014-02-12 EP EP14751025.9A patent/EP2956149B1/en active Active
- 2014-02-12 CA CA2900763A patent/CA2900763C/en active Active
- 2014-02-12 CN CN201480016889.0A patent/CN105163743A/zh active Pending
- 2014-02-12 SI SI201431336T patent/SI2956149T1/sl unknown
- 2014-02-12 CN CN201910242271.0A patent/CN109893516A/zh active Pending
- 2014-02-12 UA UAA201508775A patent/UA120249C2/uk unknown
- 2014-02-12 HU HUE14751025A patent/HUE052411T2/hu unknown
- 2014-02-12 JP JP2015558108A patent/JP6494529B2/ja active Active
- 2014-02-12 AU AU2014216373A patent/AU2014216373B2/en active Active
- 2014-02-12 MX MX2015010490A patent/MX368536B/es active IP Right Grant
- 2014-02-12 PT PT14751025T patent/PT2956149T/pt unknown
- 2014-02-12 ES ES14751025T patent/ES2744406T3/es active Active
- 2014-02-12 NZ NZ711754A patent/NZ711754A/en not_active IP Right Cessation
- 2014-02-12 WO PCT/US2014/016071 patent/WO2014127025A1/en active Application Filing
- 2014-02-12 PL PL14751025T patent/PL2956149T3/pl unknown
- 2014-02-12 RU RU2015138708A patent/RU2671400C2/ru active
- 2014-10-24 US US14/522,921 patent/US9498445B2/en active Active
-
2015
- 2015-08-06 IL IL240387A patent/IL240387B/en active IP Right Grant
- 2015-08-12 CL CL2015002253A patent/CL2015002253A1/es unknown
- 2015-08-13 PH PH12015501783A patent/PH12015501783A1/en unknown
-
2016
- 2016-04-21 US US15/135,309 patent/US9603806B2/en active Active
- 2016-05-16 HK HK16105611.0A patent/HK1217645A1/zh unknown
-
2017
- 2017-03-22 US US15/466,305 patent/US10238606B2/en active Active
-
2019
- 2019-02-13 US US16/274,634 patent/US10898439B2/en active Active
- 2019-07-18 US US16/515,621 patent/US11135172B2/en active Active
- 2019-08-29 HR HRP20191559 patent/HRP20191559T1/hr unknown
- 2019-09-02 CY CY20191100919T patent/CY1122113T1/el unknown
-
2021
- 2021-08-20 US US17/408,111 patent/US11931463B2/en active Active
-
2024
- 2024-03-01 US US18/592,784 patent/US20240325313A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501783B1 (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
| MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
| MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
| PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2013000567A (es) | Composiciones farmaceuticas de moduladores de c-met. | |
| PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
| WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX359887B (es) | Composicion masticable para administracion oral y proceso para preparar la misma. | |
| MX2016016039A (es) | Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización.. | |
| MX2015015537A (es) | Formulacion de pastillas de nicotina. | |
| WO2014065640A3 (ko) | 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물 | |
| EA201270547A1 (ru) | Фармацевтическая композиция | |
| IN2013MU03309A (es) | ||
| IN2013MU03422A (es) | ||
| IN2013MU03308A (es) | ||
| IN2013MU03428A (es) | ||
| IN2013CH02437A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |